Generic alendronate use among medicare beneficiaries: Are part d data complete?

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 1, 2013, Pages 55-63

  Yun, Huifeng ^a   Curtis, Jeffrey R ^a,b   Saag, Kenneth ^a,b   Kilgore, Meredith ^a   Muntner, Paul ^a   Smith, Wilson ^a   Matthews, Robert ^a   Wright, Nicole ^a   Morrisey, Michael A ^a   Delzell, Elizabeth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Alendronate; Generic drugs; Medicare Part D; Medication adherence; Pharmacoepidemiology

Indexed keywords

ALENDRONIC ACID; GENERIC DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; DRUG COST; DRUG WITHDRAWAL; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DRUG APPROVAL; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MEDICARE PART D; PROPORTIONAL HAZARDS MODELS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84872169892     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3361     Document Type: Article

References (12)

1. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. FDA approved Drug Products. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed Jan 31, 2012.
2. Medco Health Solutions I. 2009 Drug trend report. The great Healthcare debates. Prescriptions for meaningful reform. 2009;11.
3. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ, III. Population-based survival after osteoporotic fractures. Am J Epidemiol 1993; 137(9): 1001-1005.
4. Sikka R, Xia F, Aubert R. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11(7): 449-457.
5. Centers for Medicare & Medicaid Services. Medicare & Medicaid Statistical Supplement. Available at http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareMedicaidStatSupp/index.html Assessed on Sept 17th, 2012.
6. Taylor A, Gary L, Arora T, et al. Clinical and demographic factors associated with fractures among older Americans. Osteoporos Int 2010; 22(4): 1263-1274.
7. Yamauchi M, Sugimoto T. Frontiers in vitamin D; basic Research and clinical application. Effect of active vitamin D3 on osteoporosis. Clin Calcium Nov 2011; 21(11): 17-24.
8. Recker R, Lips P, Felsenberg D, et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin Sep 2006; 22(9): 1745-1755.
9. Jansen JP, Gaugris S, Bergman G, Sen SS. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. Curr Med Res Opin Mar 2008; 24(3): 671-684.
10. The Henry J. KAISER FAMILY Foundation. Medicare Fact Sheet. Low-income assistance under the Medicare Drug benefit. www.kff.org. 2008.
11. Priest J, Buikema A, Engel-Nitz NM, Cook CL, Cantrell R. Quality of Care, Health Care Costs, and Utilization among Medicare Part D Enrollees With and Without Low-income Subsidy. Popul Health Manag 2012; 15(2): 101-112.
12. Federman AD, Halm EA, Zhu C, Hochman T, Siu AL. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care 2006; 12(10): 611-618.